Sixmo SMC card

For UK healthcare professionals only.

The production of this Guidelines  card has been commissioned by Accord Healthcare Limited. See bottom of page for full disclaimer.

View adverse event reporting and prescribing information

Download a PDF of the Guidelines summary card


Buprenorphine (Sixmo®) 74.2mg implant SMC23721

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows:

Advice: following a full submission

Buprenorphine implant (Sixmo®) is accepted for use within NHSScotland.

Indication under review: for substitution treatment for opioid dependence in clinically stable adult patients who require no more than 8 mg/day of sublingual buprenorphine, within a framework of medical, social and psychological treatment.

Buprenorphine implant was non-inferior to buprenorphine-naloxone sublingual tablets for controlling illicit drug use in patients transferred from stable daily doses of sublingual buprenorphine up to 8mg.

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.

About the SMC

The Scottish Medicines Consortium (SMC) is part of Healthcare Improvement Scotland, the national healthcare improvement organisation for Scotland. SMC reviews new medicines that have received a licence from the Medicines and Healthcare products Regulatory Agency (MHRA – the licensing body for the UK). SMC also reviews new formulations of, and new ways to use, established medicines. Before a medicine can be prescribed routinely in Scotland, it has to be accepted for use by SMC. SMC advice helps the health service plan for the quick, uniform introduction of beneficial treatments across NHSScotland.


  1. Scottish Medicines Consortium. buprenorphine (Sixmo®) SMC2372. SMC, December 2021.

The production of this Guidelines summary card has been commissioned by Accord Healthcare Limited. Accord Healthcare Limited has reviewed the card for technical accuracy and regulatory compliance and supplied the prescribing information. This summary card only displays the concise guidance; readers are strongly advised to refer to the full guidance at:

The guidance is reproduced with permission of the Scottish Medicines Consortium (SMC). Copyright of the guidance rests with the SMC, and it may be freely reproduced for educational and not-for-profit purposes. No reproduction by, or for, commercial organisations, or for commercial purposes, is allowed without the express written permission of the SMC.

MGP Ltd owns copyright of the Guidelines brand, logo, and the design and format of this summary card.

The views and opinions expressed are not necessarily those of Guidelines, its publisher, advisers, or advertisers.


Date of preparation: April 2022